Extrachromosomal circular DNA is exactly what the name suggests: small rings of DNA that exist outside the chromosomes, looping free of the linear genome. Unlike chromosomal DNA, these circles can carry intact gene fragments and regulatory elements, and because they replicate independently of the normal cell cycle, they can be amplified rapidly in numbers. That property makes eccDNA a potent engine of oncogene overexpression, a mechanism that has been implicated in drug resistance in several cancers, including notoriously amplified circles carrying the MYC oncogene in neuroblastoma and other tumors. Yet in ovarian cancer, the interplay between eccDNA and the epigenetic machinery that controls gene activity has remained poorly charted territory.

The epigenetic machinery in question centers on histone deacetylases, or HDACs, enzymes that remove acetyl chemical groups from histone proteins around which DNA is wound. When histones are highly acetylated, DNA is more accessible and genes are more active; HDACs strip those acetyl groups away, tightening chromatin and silencing genes. In many cancers, HDAC activity is dysregulated, contributing to the abnormal silencing of tumor suppressors and the miswiring of gene-control networks. HDAC inhibitors, including the drug panobinostat, also known by its code name LBH589, were designed to reverse that silencing and restore normal gene expression patterns in tumor cells.

Panobinostat is a broad-spectrum HDAC inhibitor that has been tested in various hematologic and solid malignancies. The new study set out to ask a question that is often overlooked in drug development: what happens to the eccDNA landscape when a tumor is treated with an epigenetic drug? The answer, according to the team’s experiments, is that the drug does far more than simply reactivate silenced genes. It induces a significant remodeling of the eccDNA population within ovarian cancer cells, with a notable enrichment of circles derived from messenger RNA genes and from long noncoding RNAs, a class of regulatory RNA molecules with their own roles in cancer biology.

To connect this eccDNA remodeling to gene activity, the researchers integrated two powerful genome-wide datasets. The first came from RNA sequencing, which measures the complete set of RNA transcripts produced by the cells and therefore reveals which genes are switched up or down under treatment. The second came from chromatin immunoprecipitation sequencing, or ChIP-seq, targeted at HDAC3, one of the key histone deacetylase enzymes. ChIP-seq identifies the precise genomic locations where HDAC3 binds, marking the genes it directly regulates. By overlaying these maps with the eccDNA data, the team identified a set of 52 oncogenes that are linked to eccDNA, bound by HDAC3, and consistently upregulated by panobinostat treatment.

That convergence of three independent molecular signals, eccDNA presence, HDAC3 binding, and treatment-induced upregulation, is what gives the finding its weight. It suggests that the drug’s inhibition of HDAC3 does not uniformly suppress oncogenic potential. Instead, in at least a subset of genes, blocking HDAC3 appears to coincide with an adaptive activation program in which oncogenes carried or associated with circular DNA become more highly expressed. The authors describe this as an adaptive oncogenic response, a kind of molecular counterpunch thrown by the tumor as the epigenetic pressure of the drug takes hold.

The clinical relevance of these 52 genes was tested using survival analysis across multiple cancer cohorts. The team found that alterations in these oncogenes correlated with worse disease-free survival, meaning that patients whose tumors carried changes in these genes tended to remain cancer-free for shorter periods after treatment. This kind of population-level correlation does not prove causation on its own, but it flags the gene set as a meaningful marker of aggressive disease and provides a rationale for digging deeper into individual members of the group.

One member stood out. LMO2, a gene encoding a transcriptional regulator best known for its roles in blood cell development and, historically, as a gene disrupted in certain leukemias, emerged from the analysis as a novel oncogene in ovarian cancer. The mechanistic work behind this claim is technically detailed but conceptually clear. Supplementary analyses showed that panobinostat increases the levels of H3K27ac, an acetyl mark on histone H3 that signals active regulatory regions, at the promoter-proximal regions of the LMO2 gene, without altering HDAC3 binding at those same sites. In other words, the drug does not move HDAC3 off the DNA; it changes the chemical balance of chromatin in a way that favors LMO2 activation.

Functional experiments reinforced the picture. In TOV-112D, an ovarian cancer cell line used in the study, inhibiting HDAC3 with drugs or knocking the enzyme down with interfering RNAs both led to increased LMO2 expression. Conversely, when the researchers knocked LMO2 down, the cells became more sensitive to panobinostat. That last result is the most consequential: it implies that LMO2 upregulation is not merely a byproduct of treatment but a functional contributor to reduced drug sensitivity. A tumor that can ramp up LMO2 in response to HDAC inhibition may thereby cushion itself against the drug’s effects, and removing that cushion restores vulnerability.

The broader significance of the study lies in its demonstration that epigenetic therapy and the eccDNA layer of cancer genetics are deeply intertwined. HDAC-associated epigenetic regulation, the authors conclude, is connected to eccDNA-linked oncogene activation, and this connection may modulate how ovarian cancer patients respond to HDAC inhibitors. For clinicians, the work suggests a potential combination strategy: pairing HDAC inhibitors with approaches that suppress LMO2 or its downstream effects could prevent the adaptive escape that otherwise undermines treatment. For researchers, the study provides a template for integrating Circle-seq, RNA-seq, and ChIP-seq data to find similar vulnerabilities in other tumor types. The work, supported by funding from the National Natural Science Foundation of China and provincial programs, was conducted with approval from the Animal Welfare Committee of Fudan University Shanghai Cancer Center, and the authors report no competing interests. As the field moves toward therapies that target the nonchromosomal genome, LMO2 now stands as a concrete, testable target in the fight against ovarian cancer’s most stubborn defense mechanisms.

Subject of Research: The interplay between extrachromosomal circular DNA, HDAC3-mediated epigenetic regulation, and oncogene activation in ovarian cancer

Article Title: Integration of eccDNA and transcriptomic landscapes uncovers LMO2 as a therapeutic target in ovarian cancer

Article References: Han, T., Yan, Q., Bu, H., Gan, Y., Shen, X., Li, K., Guan, L., Dong, W., Li, P., Zhao, M., Zhou, X., Gao, B., & Hao, Q. (2026). Integration of eccDNA and transcriptomic landscapes uncovers LMO2 as a therapeutic target in ovarian cancer. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02296-3

Image Credits: AI Generated

DOI: 10.1186/s13048-026-02296-3

Keywords: eccDNA, ovarian cancer, LMO2, HDAC3, panobinostat, epigenetics, oncogene, drug resistance, transcriptomics, ChIP-seq, therapeutic target, Journal of Ovarian Research

Non-small cell lung cancer accounts for approximately 85% of lung cancer cases and remains a leading cause of cancer-related mortality worldwide. Despite advances in targeted treatments, resistance to therapies such as KRAS inhibitors persists, often leading to disease progression. KRAS mutations, particularly KRAS G12C, have long been an elusive target until the development of covalent inhibitors like adagrasib, which specifically target this mutant protein. However, monotherapy with adagrasib, while effective initially, frequently leads to acquired resistance, underscoring the urgent need for innovative combinatorial approaches.

The current study, led by Lu, H. and colleagues, centers on panobinostat, a potent histone deacetylase (HDAC) inhibitor known to modulate gene expression and impact tumor cell proliferation and survival. Previous research has hinted at HDAC inhibitors’ potential to sensitize cancer cells to other treatments by altering epigenetic landscapes. Here, the scientists propose that panobinostat can enhance adagrasib-induced cytotoxicity by promoting autophagic pathways, thereby effectively doubling down on tumor cell demise.

Autophagy, a tightly regulated catabolic process responsible for degrading and recycling cellular components, is a double-edged sword in cancer biology. While in some contexts autophagy supports tumor survival under stress conditions, its excessive activation can precipitate autophagic cell death—a non-apoptotic mechanism distinct from classical programmed cell death. The authors demonstrate that panobinostat triggers this autophagic flux in NSCLC cells, which, when combined with adagrasib treatment, results in synergistic suppression of tumor viability.

Through a series of rigorous in vitro experiments, multiple NSCLC cell lines harboring the KRAS G12C mutation were exposed to adagrasib alone or in combination with panobinostat. Cellular viability assays revealed a significant increase in apoptosis and autophagic markers in the combination therapy group compared to single treatment arms. By employing autophagy inhibitors alongside the drug regimen, the researchers confirmed that autophagy was a pivotal contributor to the enhanced cell death observed, rather than a bystander effect.

Delving deeper into the mechanistic underpinnings, the study elucidates that panobinostat’s epigenetic modulation leads to upregulation of key autophagy-related genes, such as LC3 and Beclin-1, thereby priming the cells for enhanced autophagic response upon exposure to adagrasib. This coordinated upregulation underscores the potential of epigenetic therapy as a partner to conventional targeted drugs, opening new avenues for combinatorial regimens in lung cancer management.

Beyond cell cultures, the team assessed this drug synergy in xenograft mouse models, observing marked tumor regression and prolonged survival in animals treated with both panobinostat and adagrasib compared to controls. Importantly, toxicity assessments revealed that the combination was tolerated well, with minimal adverse effects, strengthening the case for clinical evaluation of this therapeutic strategy.

This dual-triggering of apoptosis and autophagy presents an elegant strategy to tackle the pervasive issue of resistance in KRAS mutant NSCLC. By manipulating intrinsic cell death pathways, the dual treatment dismantles the cellular defenses that often thwart single-agent therapies. The findings also spark a broader implication that HDAC inhibitors could be harnessed to bolster the efficacy of a wide range of targeted cancer therapies beyond NSCLC.

The research further underscores the complexity of autophagy’s role in cancer, advocating for context-specific modulation rather than blunt inhibition. In this setting, triggering autophagy facilitated drug-induced cytotoxicity rather than promoting tumor survival, highlighting the necessity of precision medicine approaches tailored to the molecular landscape of each cancer subtype.

Intriguingly, the authors note that this synergistic effect may also intersect with immune-modulatory functions, as HDAC inhibitors are known to influence tumor microenvironment and immune checkpoints. While beyond the scope of this initial investigation, this raises compelling prospects for integrating immune-based therapies with panobinostat and adagrasib combinations in future clinical trials.

The study’s advanced use of molecular probes and biochemical assays helped paint a detailed picture of intracellular events, reinforcing the significance of comprehensive mechanistic studies in translational oncology. The revelation that panobinostat primes tumor cells to succumb more readily to adagrasib aligns with the growing ethos that combinational strategies are imperative for overcoming cancer’s adaptive prowess.

Given the mounting evidence, clinical oncologists are likely to watch closely as panobinostat is ushered into trials combined with adagrasib in KRAS mutant NSCLC patients. If these promising preclinical results translate to the clinic, it could radically redefine therapeutic paradigms for one of the most challenging lung cancer subsets.

This study also serves to remind the scientific community about the value of repurposing existing drugs like panobinostat, initially approved for hematological malignancies, in solid tumors where unmet clinical needs abound. By leveraging known pharmacological agents with newly elucidated mechanisms, research can accelerate the bench-to-bedside timeline, offering tangible benefits to patients sooner.

The ethical and economic impact of such combinatorial treatments must also be considered, as lung cancer’s global burden disproportionately affects populations with limited access to expensive therapies. Targeting autophagy via HDAC inhibition may offer a more cost-effective means to sensitize tumors, potentially improving outcomes in diverse healthcare settings.

Future research directions proposed by the authors include deciphering biomarkers predictive of response to this drug combination, as well as expanding investigations into other KRAS mutations and cancer types where autophagy modulation could be exploited therapeutically. This comprehensive framework will be critical for tailoring treatments to individual molecular profiles.

In sum, this seminal work by Lu et al. propels our understanding of NSCLC biology forward by bridging epigenetic therapy with targeted inhibition through autophagy induction. The elegant synergy between panobinostat and adagrasib heralds a new chapter in the relentless battle against lung cancer, promising hope for improved survival and quality of life for patients worldwide.

As scientists continue to unravel the intricacies of cancer’s survival tactics, the integration of multi-modal therapeutic strategies that blend targeted drugs with epigenetic and metabolic modulators is poised to deliver unprecedented clinical advances. This study stands as a beacon, exemplifying how meticulous molecular dissection can translate into transformative treatment concepts.

The potential of this breakthrough extends beyond lung cancer, offering a scalable blueprint for combatting other malignancies where resistance mechanisms undermine targeted therapy success. The road ahead will undoubtedly involve complex clinical validation, yet the horizon gleams with optimism fueled by these innovative insights into autophagy and epigenetic synergy.

Subject of Research: Human Non-Small Cell Lung Cancer (NSCLC) and the synergistic effects of panobinostat and adagrasib on triggering autophagy-induced cell death.

Article Title: Panobinostat potentiates adagrasib-induced cell death by triggering autophagy in human non-small cell lung cancer.

Article References:
Lu, H., Fu, W., Xia, Y. et al. Panobinostat potentiates adagrasib-induced cell death by triggering autophagy in human non-small cell lung cancer. Cell Death Discov. 11, 360 (2025). https://doi.org/10.1038/s41420-025-02657-9

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-025-02657-9